摘要
目的探讨高压氧治疗(HBOT)对未行静脉溶栓治疗的醒后卒中(WUS)患者血清炎性因子、氧化低密度脂蛋白(ox-LDL)水平的影响。方法选取2022年11月至2023年12月收治的WUS患者94例,采用随机数字表法分为观察组与对照组各47例,观察组予常规药物联合HBOT,对照组予常规药物治疗,均治疗1个月。对比两组治疗前后血清炎性因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]和ox-LDL水平;评估发病7、14、30 d后美国国立卫生研究院卒中量表(NIHSS)与改良Rankin量表(mRS)评分变化,并评估治疗安全性。结果治疗后两组血清hs-CRP、IL-6、TNF-α、ox-LDL水平均降低,且观察组均低于对照组(P<0.05,P<0.01)。两组治疗7、14及30 d NIHSS与mRS评分均较治疗前显著降低(P<0.05);治疗14、30 d观察组NIHSS与mRS评分均低于对照组(P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论HBOT辅助治疗可降低未行静脉溶栓治疗的WUS患者血清炎性因子和ox-LDL水平,改善神经功能缺损程度及预后,且安全性良好。
Objective To explore the impact of hyperbaric oxygen-assisted therapy(HBOT)on the levels of serum inflammatory factors and oxidized low-density lipoprotein(ox-LDL)in patients with wake-up stroke(WUS)who did not receive intravenous thrombolytic therapy.Methods A total of 94 patients with WUS admitted from November 2022 to December 2023 were selected and divided into the observation group and the control group,with 47 patient in each group,using a random number table.The observation group was treated with conventional drugs combined with HBOT,while the control group was treated with conventional drugs.Both groups were treated for one month.The levels of serum inflammatory factors[highsensitivity C reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]and ox-LDL before and after treatment were compared between the two groups.The changes in the scores of the National Institutes of health stroke scale(NIHSS)and the Modified rankin scale(mRS)at 7,14,and 30 d after the onset of the disease,and the safety of treatment were evaluated.Results After treatment,the levels of serum hs-CRP,IL-6,TNF-α and ox-LDL in both groups decreased,which were lower in the observation group than in the control group(P<0.05,P<0.01).The NIHSS and mRS scores of both groups at 7,14 and 30 d after treatment were significantly lower than those before treatment(P<0.05).At 14 and 30 d aftertreatment,the NIHSS and mRS scores of the observation group were lower than those of the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion HBOT adjuvant therapy can reduce the levels of serum inflammatory factors and ox-LDL in WUS patients who have not received intravenous thrombolytic therapy,improve the degree of neurological deficits and prognosis,and has good safety.
作者
李燃
张赟
岳秉宏
智永怡
翟晓媛
刘星亮
LI Ran;ZHANG Yun;YUE Binghong;ZHI Yongyi;ZHAI Xiaoyuan;LIU Xingliang(Department of Neurology,the First Affiliated Hospital of Hebei North College,Zhangjiakou,Hebei 075000,China)
出处
《临床误诊误治》
2025年第17期65-69,共5页
Clinical Misdiagnosis & Mistherapy
基金
张家口市重点研发计划项目(2221133D)。
关键词
高压氧
醒后卒中
静脉溶栓
超敏C反应蛋白
白细胞介素-6
肿瘤坏死因子-α
氧化低密度脂蛋白
hyperbaric oxygen
wake-up stroke
intravenous thrombolysis
high-sensitivity C reactive protein
interleukin-6
tumor necrosis factor-α
oxidized low-density lipoprotein
